the Index to Scientific and Technical Proceedings and the clinical trials registry (http://clinicaltrials. gov) were also searched.
Study selection Randomised controlled trials (RCTs) involving
nucleoside antiviral agents for the prevention of recurrent oral herpes in healthy immunocompetent subjects ≥12 years old were included.
No language restrictions were applied. Study quality was assessed following Cochrane guidelines.
Data extraction and synthesis Data were abstracted using a standardised data extraction form and analysed with meta-analysis carried out only with studies that reported the same outcome measure.
Results Ten studies were included, only one study was considered to have a low risk of bias, five an unclear risk and four a high risk of bias.
Oral acyclovir (800-1,600 mg daily) and valacyclovir (500 mg daily for four months) were shown to be effective in the prevention of RHL when taken prior to the appearance of any symptoms or exposure to triggers.
Conclusions This review found support for the use of systemic acyclovir and valacyclovir for the prevention of RHL. However, the findings from this review should be interpreted with caution, because the methodologic assessment of the quality of the included studies showed an unclear risk of bias in five out of the ten included papers, and a high risk of bias in four studies. Inclusion and exclusion criteria were clearly listed. Ten studies were finally selected which met the inclusion criteria. A quality assessment using standardised tools was performed and it was determined that only one study had a low risk of bias. From the ten studies seven were parallel groups and three were crossover studies comparing different formulations of antivirals. There were seven studies of acyclovir versus placebo (topical and systemic), one for valcyclovir versus placebo and one for famcyclovir versus placebo.
Heterogeneity was calculated examining the type of intervention and the outcome measure. Due to the high heterogeneity calculated, subgroup analysis was done for each pharmacological intervention.
The results from the review show that there is a statistically significant difference in favour of systemic antiviral agents (R.R. 0.70, 95%
C.I. 0.55-0.89) such as oral acyclovir 800-1600 mg daily and valcyclovir 500mg daily for four months. Famcyclovir showed no effect compared to placebo. The most common side effects reported by both treatment and placebo groups were headache and nausea.
Patients across various studies were exposed to different triggers and protocols (such as different time and dosage of application).
All the studies compared an antiviral drug with placebo. None of them compared one antiviral drug regimen to another. Based on the results it seems there is a small benefit to using systemic antivirals for the prevention of RHL, however future RCTs with more standardised protocols and outcomes will be valuable in assessing the efficacy and thereby the recommendation of antivirals agents.
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